For PAM / Patient Support leadership

Your PSP Vendor May Change. Your Programme Intelligence Shouldn't.

Measure PSP effectiveness today and protect programme continuity across vendors tomorrow. Connect risk signals, assigned actions, documented resolution and subsequent treatment status, even when a PSP already provides reports.

Book a programme demo
Illustrative dashboard
Illustrative PACE programme overview: hospitals, HCPs, nurses, drugs in use, response rate and dropout rate.
Illustrative PACE care provider performance: in-house team and two PSP partners compared on the same measures.
Illustrative PACE vendor transition: one drug run by PSP Partner A with PSP Partner B incoming, and a plan-a-change action.

  • Detect persistence risk earlier

    Identify delayed, missed or extended treatment patterns before avoidable discontinuation.

  • Prioritise smarter

    Focus PSP capacity on the patients and unresolved cases that need action most.

  • Verify action

    Track whether intervention happened, whether the barrier was resolved and what happened next.

  • Protect continuity

    Reduce avoidable interruption and preserve programme context across vendor changes.

  • Measure programme value

    Connect PSP execution to measurable continuity and programme outcomes.

Why PACE when your PSP already has software?

Your vendor reports what it delivers. PACE helps you govern what it achieves.

Keep the PSP platform you already pay for. Add a separate, consistently defined view of treatment-continuity risks, action quality, programme effectiveness and authorised provider transitions.

01 · Existing PSP vendor system

Runs and reports its assigned work.

Patient engagement, follow-up activity, case records and vendor-specific performance dashboards.

  • Activity and service delivery
  • Vendor-defined operational reports
  • Data within the current contract

PACE Align · Independent layer

Measures continuity and accountability across providers.

Standardise metrics, connect risk to nurse action and documented outcome, assess PSP effectiveness and preserve authorised continuity context when contracts change.

  • Consistent cross-provider KPIs
  • Intervention-to-outcome tracking
  • Vendor transition and programme memory

Both systems can work together. An existing PSP platform manages service delivery. PACE adds sponsor-defined continuity and effectiveness measurement across authorised providers.

No second PSP operation required. PACE can integrate with approved existing CRM, EHR and FHIR-enabled workflows through scoped interfaces and structured data exchange.

One case, two questions

Was the activity completed, or was the risk resolved?

See the difference in a single fictional programme case. Both the PSP operational record and PACE continuity oversight can contribute to the same answer.
Illustrative example only

Provider delivery view

Follow-up completed

Case P-0418 · Nurse call recorded

The team contacted the patient and documented the outreach. That confirms activity, but it does not establish that the underlying barrier was resolved.

PACE / sponsor governance

Resolution still requires verification

Access barrier open · Next treatment status pending

PACE can connect the recorded action with unresolved risk, owner accountability, and subsequent treatment status, using authorised data and programme-defined measures.

The purchasing argument: PACE helps PAM govern programme effectiveness independently of how a single vendor chooses to report its activity. No claim that existing PSP software cannot track outcomes.

The everyday business case

Measure PSP effectiveness today. Preserve programme continuity tomorrow.

A vendor transition is one reason to use PACE. The everyday reason is to understand whether patient-support risks receive timely, accountable action, and what is documented afterwards.
  1. 1

    Risk identified

    Relevant treatment-continuity signal

  2. 2

    Owner assigned

    Accountable PSP team member

  3. 3

    Action recorded

    Intervention and timestamp

  4. 4

    Resolution checked

    Barrier status documented

  5. 5

    Continuity tracked

    Subsequent treatment information

Recording a treatment event following an intervention is not, by itself, evidence that the intervention caused persistence or preserved revenue.

Current challenge

  • Fragmented visibility

    Periodic reports leave no live view of persistence risk, unresolved needs and response progress.

  • Unclear intervention insight

    Activity is visible, but resolution and subsequent treatment status may not be.

  • Persistence risk appears too late

    Treatment-rhythm deviation may emerge before a complaint or discontinuation.

  • Vendor dependency

    Programme intelligence can sit inside one operator’s environment.

  • Inconsistent data & KPIs

    Comparison across programmes and providers becomes difficult.

  • Continuity risk

    Provider changes can disrupt context, open follow-ups and longitudinal history.

  • Difficult to demonstrate realised programme value

    Leadership needs evidence of execution, continuity and outcomes.

7 ways PACE strengthens PAM governance

  • 1

    Independent visibility

    Real-time, de-identified visibility across programmes and PSP vendors.

  • 2

    Early persistence-risk identification

    Detect delayed, missed or extended treatment patterns before avoidable discontinuation.

  • 3

    Intelligent prioritisation

    Focus PSP capacity on patients who need action most based on risk and programme context.

  • 4

    Verified PSP execution

    Know whether intervention happened and whether the barrier was resolved.

  • 5

    Measurable intervention effectiveness

    Distinguish activity from actions associated with documented resolution and continuity.

  • 6

    Consistent programme intelligence

    Use consistent KPI definitions and longitudinal views across vendors and time.

  • 7

    Programme continuity across vendor changes

    Preserve authorised programme context, open follow-ups and agreed measures through transition.

Decision areas

  • Treatment-rhythm risk

    Aggregated persistence-risk patterns and movement over time.

  • PSP execution

    Open/ageing cases, response progress, unresolved barriers and documented resolution.

  • Continuity

    Persistence, interruptions, discontinuation and follow-through completeness.

  • Provider performance

    Consistent measures by programme/provider without exposing patient or HCP identities.

  • Transition continuity

    Structured handover of authorised history, open work and next steps.

PSP transition and continuity

Change PSP vendors. Keep the programme’s memory.

Keep authorised open cases, assigned owners, outstanding follow-ups and consistent KPI definitions visible when contracts or PSP providers change.

  1. Outgoing PSP

    Provider A

    Open cases, authorised history, work queues

  2. PACE Align

    Continuity layer

    Structured data, case mapping, acceptance log, consistent metrics

  3. Incoming PSP

    Provider B

    Verified handover, responsible owner, live workflow

Contractual data rights, consent, approved sharing and access boundaries determine what may transfer. No uncontrolled patient-data exchange.

One value proposition, two purchase paths

Independent governance need not mean another disconnected vendor.

PACE can be evaluated through a direct pharmaceutical arrangement or, where commercially and contractually appropriate, delivered through an existing PSP partner.

Route A

Pharma-sponsored intelligence

For buyers seeking an explicitly governed, vendor-independent performance layer across one or more PSP operators.

Decision owner:
PAM
Review:
Procurement / IT / Privacy
Discuss pharma procurement

Route B

PSP-integrated deployment

For a sponsor that prefers existing PSP contracting structures, while retaining defined sponsor reporting rights and oversight.

Decision:
PAM + PSP partner
Review:
Contractual data rights
Explore PSP-integrated route

Implementation, information access and contractual independence depend on approved data-sharing arrangements. No procurement acceptance or integration is implied.

Review the enterprise evaluation route

Bring one programme challenge. See how PACE addresses it.

See persistence risk, provider follow-through and continuity for one programme, and agree the proof-of-value measures a pilot should test.

Book a programme demoEstimate potential revenue preserved

Pilot proof-of-value measures

  • Time from risk signal to action
  • Overdue follow-ups
  • Ageing unresolved cases
  • Documented resolution
  • Persistence / discontinuation
  • Handover completeness